首页|期刊导航|中国医院用药评价与分析|头孢比罗酯钠在耐甲氧西林金黄色葡萄球菌血流感染中应用的研究进展

头孢比罗酯钠在耐甲氧西林金黄色葡萄球菌血流感染中应用的研究进展OA

Progress on Application of Ceftobiprole Medocaril Sodium in the Treatment of Blood Stream Infection Induced by Methicillin Resistant Staphylococcus aureus

中文摘要英文摘要

多重耐药菌引起的血流感染仍是全球性的公共卫生问题之一,具有较高的发病率和死亡率.头孢比罗酯钠作为第 5 代头孢菌素,对包括耐甲氧西林金黄色葡萄球菌在内的多种革兰阳性菌和革兰阴性菌具有活性,是治疗复杂和潜在耐药性感染的潜力药物.该文综述了头孢比罗酯钠的作用机制、抗菌活性,以及其在耐甲氧西林金黄色葡萄球菌血流感染中的临床应用,为临床合理选择和使用药物提供参考.

Blood stream infection induced by multi-drug resistant bacteria is still one of the global public health problems with high incidence rate and mortality.Ceftobiprole medocaril sodium is the fifth generation cephalosporin,which has activity against various Gram-positive including methicillin resistant Staphylococcus aureus and Gram-negative bacteria.Ceftobiprole medocaril sodium is a potential drug for treatment of complex and potentially drug-resistant infections.This article reviews the mechanism of action,antibacterial activity,and clinical application of ceftobiprole medocaril sodium in blood stream infections induced by methicillin resistant S.aureus,providing reference for rational selection and use in clinical practice.

吕鹏;张倩;黄怡菲;张卓

皖南医学院附属太和医院药剂科,安徽 阜阳 236600皖南医学院附属太和医院中医内科,安徽 阜阳 236600华中科技大学同济医学院附属协和医院药学部,武汉 430022新疆生产建设兵团第六师医院药学部,新疆 五家渠 831300

医药卫生

头孢比罗酯钠耐甲氧西林金黄色葡萄球菌血流感染研究进展

Ceftobiprole medocaril sodiumMethicillin resistant Staphylococcus aureusBlood stream infectionResearch progress

《中国医院用药评价与分析》 2026 (3)

380-384,5

国家卫生健康委医院管理研究所2024年医疗质量(循证)管理研究项目(No.YLZLXZ24G047)

10.14009/j.issn.1672-2124.2026.03.028

评论